Inhibition of acalabrutinib metabolism by finerenone and its molecular docking s...

연구 요약

Inhibition of acalabrutinib metabolism by finerenone and its molecular docking studies.

Cell biology and toxicology 학술지에 발표된 이 연구는 Wang P, Fu H, Wu J 외 연구팀이 수행하였습니다.

이 연구는 'Inhibition of acalabrutinib metabolism by finerenone and its molecular docking studies.'에 대한 과학적 분석을 제공합니다.

핵심 내용

Acalabrutinib is a frontline agent for chronic lymphocytic leukemia (CLL). The objective of this experiment was to screen 21 cardiovascular drugs with a focus on elucidating the metabolic inhibition of acalabrutinib by finerenone in vitro and in vivo. The ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) was applied to quantify acalabrutinib and its major active metabolite ACP-5862 in liver microsomes in vitro and in rats in vivo. The half-maximal inhibitory concentrations (IC50) of finerenone in rat liver microsomes (RLM), human liver microsomes (HLM) and recombinant human CYP3A4 (rCYP3A4) were 7.00, 21.29 and 3.52 μM, respectively. In RLM and rCYP3A4, finerenone inhibited the metabolism of acalabrutinib via mixed-type inhibition (competitive and non-competitive), with a non-competitive inhibition observed in HLM. Compared with the control group, in vivo pharmacokinetic analysis indicated that finerenone co-administration increased acalabrutinib exposure, as reflected by 4.08-, 7.16-, and 3.96-fold increases in AUC(0-t), AUC(0-∞), and half-life (t1/2), respectively, accompanied by an 86.02% reduction in the clearance (CLz/F). Its metabolite ACP-5862 demonstrated a 57.47% and 65.12% decrease in AUC(0-t) and the maximum concentration (Cmax), respectively, while CLz/F was increased by 0.79-fold. Finally, acalabrutinib and finerenone were evaluated for binding to cytochrome P450 3A4 (CYP3A4) by molecular docking, yielding binding energies of -2.36 and -2.19 kcal/mol, respectively. Thus, in vivo and in vitro results consistently indicated that finerenone inhibited the metabolism of acalabrutinib, providing the basis for individualized dosing considerations.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41673329)

📄 [전문 보기 (Markdown)](fulltext/41673329-inhibition-of-acalabrutinib-metabolism-by-finerenone-and-its.md)